Ziopharm up 15% on Intrexon/Merck Serono deal

|By:, SA News Editor

Ziopharm (NASDAQ:ZIOP) jumps 15% premarket on robust volume in response to Intrexon's announcement of a collaboration with Merck Serono. Intrexon will share the economic benefits of the partnership equally will Ziopharm based on their joint license deal with MD Anderson Cancer Center.

Previously: Intrexon and Ziopharm set for opening gaps (Feb. 10)

Previously: Intrexon and Merck Serono team up in cancer immunotherapy (March 30)

Subscribe for full text news in your inbox